Detalhe da pesquisa
1.
Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome.
Drug Metab Dispos
; 45(5): 501-511, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28254951
2.
Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates.
Diabetes Obes Metab
; 19(12): 1762-1772, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28573777
3.
Liver-Targeted Small-Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis.
Angew Chem Int Ed Engl
; 56(51): 16218-16222, 2017 12 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29073340
4.
Stochastic gene expression out-of-steady-state in the cyanobacterial circadian clock.
Nature
; 450(7173): 1249-52, 2007 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-18097413
5.
A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody Programs.
Front Bioinform
; 1: 731340, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-36303796
6.
Fc-GDF15 glyco-engineering and receptor binding affinity optimization for body weight regulation.
Sci Rep
; 11(1): 8921, 2021 04 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-33903632
7.
Analysis of mechanistic pathway models in drug discovery: p38 pathway.
Biotechnol Prog
; 24(1): 96-109, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-17918858
8.
Assessing the Feasibility of Neutralizing Osteopontin with Various Therapeutic Antibody Modalities.
Sci Rep
; 8(1): 7781, 2018 05 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29773891
9.
Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents.
J Med Chem
; 61(13): 5704-5718, 2018 07 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29878763
10.
Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing.
Sci Rep
; 8(1): 4241, 2018 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29523796
11.
Physiologically relevant binding affinity quantification of monoclonal antibody PF-00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlation.
Br J Pharmacol
; 174(1): 70-81, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27760281
12.
A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects.
Cell Metab
; 23(3): 427-40, 2016 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26959184
13.
Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice.
PLoS One
; 10(3): e0119104, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25790234
14.
Comprehensive mechanism-based antibody pharmacokinetic modeling.
Annu Int Conf IEEE Eng Med Biol Soc
; 2011: 4318-23, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-22255295
15.
Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro.
BMC Syst Biol
; 4: 23, 2010 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20230629
16.
Cellular imaging predictions of clinical drug-induced liver injury.
Toxicol Sci
; 105(1): 97-105, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18524759
17.
Probing polymerization forces by using actin-propelled lipid vesicles.
Proc Natl Acad Sci U S A
; 100(8): 4521-6, 2003 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12657740